Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oculis Eyes Opportunities With Fresh Funding and Novartis Licensing Deal

Executive Summary

As Novartis looks to move out of much of its ophthalmology research with the forthcoming spinoff of Alcon, fellow Swiss firm Oculis has licensed one of its assets and secured new financing to progress its back-of-the-eye treatments.

Advertisement

Related Content

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Narasimhan: Novartis' Specialized Portfolio Will Lead To Bigger Breakthroughs And Greater Value

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel